Celltrion has become the latest firm to enter the US market for Stelara (ustekinumab) biosimilars, with its Steqeyma (ustekinumab-stba) version representing the sixth rival to the $10bn brand to be launched this year under a series of settlements with originator J&J.
The firm received US Food and Drug Administration approval for Steqeyma late last year. While it had in August 2023 announced its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?